Expect to See More HIV Meds Containing "Integrase Inhibitors"

October 2018

Updated guidelines will lead to a shift in preferred meds for treating HIV in adults.

Expect more patients to start regimens with "integrase inhibitors"...especially bictegravir (Biktarvy) or dolutegravir (Tivicay, etc).

That's because integrase inhibitors are often better tolerated than other HIV meds...and generally have fewer drug interactions.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza Sort Through Influenza Vaccine Options for 2018-19
Generics Be Ready for Generic Tadalafil and Vardenafil
Medicare Answer Questions About 2019 Medicare Part D Changes
Epinephrine Clear Up Confusion About EpiPen Shortages and Generics
Endometriosis Watch for Orilissa, a New Med for Endometriosis
Practice Remember "Cooler Heads Prevail" When Conflict Arises
Dermatology Know How Diaper Rash Remedies Stack Up
Pharmacogenetics Keep the Role of Pharmacogenetic Testing for Mental Health Meds in Perspective
Natural Medicines Focus on Safety if Patients Use Essential Oils
Antipsychotics Aristada Initio and Perseris Will Be the Latest Injectable Antipsychotics
HIV & AIDS Expect to See More HIV Meds Containing "Integrase Inhibitors"